Skip to content
Tech News
← Back to articles

Super-potent opioids could be safer-than-expected alternatives to conventional painkillers

read original more articles
Why This Matters

Recent research suggests that super-potent opioids may offer safer alternatives to traditional painkillers by reducing side effects and misuse risks. This development could significantly impact pain management strategies, potentially alleviating the opioid crisis and improving patient safety. However, further studies are needed to confirm their efficacy and safety profiles.

Key Takeaways

Opioids, including morphine, are the gold standard for pain management. Yet they are accompanied by a considerable number of side effects and a high risk of misuse1,2. The side effects include phenomena such as tolerance and dependence, and symptoms such as nausea, constipation, and, crucially, respiratory depression, which is the main cause of death after an overdose. Opioids exert their pain-relieving (analgesic) and euphoric effects mainly through the µ-opioid receptor (MOR), the activation of which strongly influences brain circuits that mediate reward and reinforcement1,2. Chronic exposure to opioids can progressively rewire these circuits, contributing to the development of opioid-use disorder. These mechanisms help to explain the opioid crisis observed in the United States and other countries, and they underscore the pressing need for alternative analgesics with reduced adverse effects. Writing in Nature, Gomez et al.3 report a step along the way to this long-sought4 goal.

doi: https://doi.org/10.1038/d41586-026-00806-3

References Darcq, E. & Kieffer, B. L. Nature Rev. Neurosci. 19, 499–514 (2018). Mathis, V. P., Ehrlich, A. T. & Darcq, E. Nature Rev. Neurosci. 26, 778–797 (2025). Gomez, J. L. et al. Nature https://doi.org/10.1038/s41586-026-10299-9 (2026). Kieffer, B. L. & Evans, C. J. Cell 108, 587–590 (2002). Manglik, A. et al. Nature 537, 185–190 (2016). Stahl, E. L. et al. Nature 650, 500–508 (2026). Ehrlich, A. T., Kieffer, B. L. & Darcq, E. Expert Opin. Ther. Targets 23, 315–326 (2019). United Nations Office on Drugs and Crime. World Drug Report 2025 (UNODC, 2025). Ujváry, I. et al. ACS Chem. Neurosci. 12, 1072–1092 (2021). Koch, T. & Höllt, V. Pharmacol. Ther. 117, 199–206 (2008). Volkow, N. D. & Blanco, C. Mol. Psychiatry 26, 218–233 (2021). Download references

Competing Interests The authors declare no competing interests.

Related Articles

Subjects